Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
Targets |
(Papain-like protease (PLpro)(IC50 = 2.6 µM);SARS-CoV-2 PLpro(IC50 = 5.0 µM);SARS-CoV-2 PLpro(EC50= 21.0 µM)
|
---|---|
ln Vitro |
Strongly inhibiting the papain-like protease (PLpro) produced by the coronavirus that causes severe acute respiratory syndrome (SARS-CoV) is PLpro inhibitor. The IC50 value of PLpro inhibitor was determined to be 2.6 μM. With EC50 values of 13.1 μM, the PLpro inhibitor exhibits strong antiviral activity and is safe at the highest tested concentration. Notably, the in vitro inhibition of PLpro correlates with increasing antiviral potency, indicating that the compounds act directly on the enzyme in cells[1][2].
|
References |
|
Molecular Formula |
C22H22N2O2
|
---|---|
Molecular Weight |
346.42228
|
Exact Mass |
346.17
|
Elemental Analysis |
C, 76.28; H, 6.40; N, 8.09; O, 9.24
|
CAS # |
1093070-14-4
|
Appearance |
Solid powder
|
SMILES |
O=C(C1=CC(NC(C)=O)=CC=C1C)N[C@H](C)C2=C(C=CC=C3)C3=CC=C2
|
InChi Key |
KGPYBLOBHQLIET-OAHLLOKOSA-N
|
InChi Code |
InChI=1S/C22H22N2O2/c1-14-11-12-18(24-16(3)25)13-21(14)22(26)23-15(2)19-10-6-8-17-7-4-5-9-20(17)19/h4-13,15H,1-3H3,(H,23,26)(H,24,25)/t15-/m1/s1
|
Chemical Name |
(R)-5-acetamido-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide
|
Synonyms |
PLpro inhibitor, KOM70144; KOM-70144; KOM 70144;
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : 69~100 mg/mL ( 199.18~288.67 mM )
Ethanol : ~35 mg/mL |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.22 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.22 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.8867 mL | 14.4333 mL | 28.8667 mL | |
5 mM | 0.5773 mL | 2.8867 mL | 5.7733 mL | |
10 mM | 0.2887 mL | 1.4433 mL | 2.8867 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
High-throughput screening using a ubiquitin-like peptide substrate identifies a PLpro inhibitor. [1].Proc Natl Acad Sci U S A, 2008. 105(42): p. 16119-24. td> |
PLpro inhibitors follow a structure–activity relationship and have antiviral activity against SARS coronavirus. [1].Proc Natl Acad Sci U S A, 2008. 105(42): p. 16119-24. td> |
Inhibitor GRL0617 binds within the S3 and S4 subsites of PLpro and induces loop closure over the inhibitor. [1].Proc Natl Acad Sci U S A, 2008. 105(42): p. 16119-24. td> |